Literature DB >> 12135428

Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens.

E H Warren1, B E Otterud, R W Linterman, A G Brickner, V H Engelhard, M F Leppert, P J Martin, S R Riddell.   

Abstract

We have evaluated the utility of genetic linkage analysis to identify genes that encode minor histocompatibility antigens using vaccinia virus vectors as a simple and convenient method for transient expression of class I MHC molecules in lymphoblastoid cell lines. As a test case, we used a CTL clone that recognizes HA-8, a minor histocompatibility antigen encoded by the KIAA0020 gene and presented by HLA-A*0201. EBV-transformed B cell lines from individuals in three large pedigrees from the CEPH reference family collection were infected with a recombinant vaccinia virus vector encoding an HLA-A*0201 transgene, which led to high level expression of the MHC restricting allele HLA-A*0201 on the cell surface. HA-8 expression in the vaccinia-infected target cells was then determined using standard in vitro cytotoxicity assays. Pairwise linkage analysis of the segregation of HA-8 expression in these pedigrees demonstrated that the HA-8 gene was tightly linked with a cluster of marker loci located on the distal portion of chromosome 9p. Analysis of 9p marker haplotypes for individuals in the three families identified several individuals with recombinant haplotypes, and these recombination events were used to refine the precision of the HA-8 gene localization further. The data collectively indicate that the HA-8 gene is localized to a 10.3 cM (corresponding to 3.9 Mb) interval of distal 9p that is thought to encode at least 11 genes, including KIAA0020. These results demonstrate that linkage analysis can be used to map minor histocompatibility genes with high precision and accuracy. Over the next years, refinement and annotation of the human genome sequence will undoubtedly increase the utility of linkage analysis as a tool for identifying minor histocompatibility antigen genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135428     DOI: 10.1034/j.1399-0039.2002.590407.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  12 in total

1.  Expanding the immunotherapeutic potential of minor histocompatibility antigens.

Authors:  Eric Spierings; Els Goulmy
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

4.  Identification of minor histocompatibility antigens based on the 1000 Genomes Project.

Authors:  Rimke Oostvogels; Henk M Lokhorst; Monique C Minnema; Maureen van Elk; Kelly van den Oudenalder; Eric Spierings; Tuna Mutis; Robbert M Spaapen
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

5.  Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Authors:  Marie Bleakley; Brith E Otterud; Julia L Richardt; Audrey D Mollerup; Michael Hudecek; Tetsuya Nishida; Colette N Chaney; Edus H Warren; Mark F Leppert; Stanley R Riddell
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

Review 6.  Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms.

Authors:  Anthony G Brickner
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 7.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

Review 8.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

9.  Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Authors:  R Oostvogels; M C Minnema; M van Elk; R M Spaapen; G D te Raa; B Giovannone; A Buijs; D van Baarle; A P Kater; M Griffioen; E Spierings; H M Lokhorst; T Mutis
Journal:  Leukemia       Date:  2012-10-01       Impact factor: 11.528

10.  Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.

Authors:  Yoshiki Akatsuka; Tetsuya Nishida; Eisei Kondo; Mikinori Miyazaki; Hirohumi Taji; Hiroatsu Iida; Kunio Tsujimura; Makoto Yazaki; Tomoki Naoe; Yasuo Morishima; Yoshihisa Kodera; Kiyotaka Kuzushima; Toshitada Takahashi
Journal:  J Exp Med       Date:  2003-05-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.